13 September 2018
The European Medicines Agency (EMA) has pulled all contracts with the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) ahead of the UK withdrawing from the EU next year. The EMA has instead redistributed the UK’s product portfolio to other EU members – prompting questions about the potential impacts of Brexit on healthcare and what will fill the gap for the MHRA.
Mathys & Squire Life Sciences Partner, Martin MacLean, provided insight on this development which has since been featured in PharmSource, European Pharmaceutical Manufacturer and Labiotech. Please click the images below to download the articles and read Martin’s commentary.
For further information regarding Brexit and the EMA or intellectual property developments in the Life Sciences and Chemistry field, please contact Martin on [email protected] or call 0207 830 0000 to speak with a patent attorney in our Life Sciences team.
Martin Maclean is a Band 1 Patent Attorney and a member of the Life Sciences Committee for the Chartered Institute of Patent Attorneys. He has consistently been nominated by peers as one of the world’s leading practitioners in the field of patents featuring in the 2016, 2017 and 2018 editions of Who’s Who Legal: Patents and has also been ranked in the latest edition of IAM Strategy 300 – The World’s Leading IP Strategists 2017.
Sign up to our mailing list to receive Mathys Matters, our monthly newsletter covering the latest IP news, industry insights, events and case law.
If you are interested in receiving quarterly newsletters relevant to our core sector groups - IT & engineering ('Inside Wires') and life sciences & chemistry ('Under the Microscope') - please select your preference(s) below:
Please select your practice area(s) of interest: